Copy
View this email in your browser
Monthly Newsletter – February 2021

Friends and Colleagues,
 
Over the last few weeks, our team has worked hard to solidify not only our first new investment of 2021, but to bring new industry experts in to advise a number of our portfolio companies. We continue to grow our internal team and are still actively looking for experienced professionals across the investment team and business services. Please see our open positions here.
 
Here’s a quick preview of the highlights from the past several weeks:

Sincerely,
David Michael, David Seldin, and Whitney Haring-Smith

PORTFOLIO COMPANY UPDATES


Anzu Partners Joins $60 Million Financing Round in Excision BioTherapeutics to Advance CRISPR-Based Infectious Disease Programs

Anzu is pleased to add Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies, to our portfolio. The company recently announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simplex Virus, and EBT-107 for Hepatitis B.

The financing round was led by GreatPoint Ventures with support from existing investor ARTIS Ventures. Other new investors include Adjuvant Capital, Norwest Venture Partners, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, and Olive Tree Capital. 

Click here to read the full press release.

ImmunoScape Announces Formation of Scientific Advisory Board and New Chief Business Officer to Lead U.S. Expansion

ImmunoScape recently announced the formation of its Scientific Advisory Board composed of leading scientists in immunology and oncology who will guide the company’s scientific strategy. Founding members include:
Evan Newell, Ph.D., who will serve as Chairman of the SAB. Dr. Newell is a co-founder of ImmunoScape and Associate Professor in the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center

 
Philip Greenberg, MD., who is an internationally recognized expert in cancer immunotherapy and currently serves as the Head of Immunology at the Fred Hutchinson Cancer Research Center

 
Patrick Reeves, Ph.D., who is a Team Leader in the Vaccine and Immunotherapy Center at Massachusetts General Hospital and an instructor in medicine at Harvard Medical School; and 

 
Paul Thomas, Ph.D., who is a Member in the Department of Immunology at St. Jude Children’s Research Hospital and an adjunct Professor in the Department of Microbiology and Immunology at the University of Tennessee Health Sciences Center.
 
 
Click here to read the full press release for details on the SAB. 
ImmunoScape also announced that they established its U.S. headquarters in San Diego and hired experiencedbiotech executive Geoff Nosrati, Ph.D. to lead the expansion as Chief Business Officer.

Before joining ImmunoScape, Dr. Nosrati advised biotechnology clients at McKinsey & Co., with a focus on corporate strategy, finance, due diligence and M&A. He most recently held senior executive positions at Aduro Biotech, a company focused on development of therapies for both oncology and renal disease, where he led strategy and corporate development. 

Click here to read the full press release on Dr. Nosrati and the U.S. expansion. 
          

FLEx Lighting Rebrands as Azumo, Maker of LCD 2.0 ™ Technology Providing Better Visibility and Longer Battery Life

FLEx Lighting, maker of LCD 2.0™ screen technology, officially announced its rebrand to Azumo. Its new name reflects the company’s efforts to advance display technology. With Azumo-powered displays, devices can run for a week on a single charge and can go wherever we need them to with visibility in direct sun and pitch darkness.
 
Click here to read the full press release.

 
 
Voltaiq Appoints Industry Pioneers to Strategic Advisory Board to Drive Electrification Innovation
 
Voltaiq announced additions to its Advisory Board representing industry trailblazers among automotive, consumer electronics and battery cell manufacturers. This group of thought leaders from around the world brings together expertise to solve global challenges in understanding and optimizing battery behavior in real-world application settings. 
 
Some of the new members include: 
Rick Wagoner, the former Chairman and CEO of General Motors


 
 
Carl-Peter Forster, who served as General Motors Automotive Strategy Board (ASB) member, CEO and President of General Motors Europe, and as CEO of Tata Motors where he was responsible for Jaguar LandRover; and 

 
Peter Haeussermann, the General Manager of Mitsubishi Electric, amongst many other industry experts. 



To see the full list of board members and the experience they bring to Voltaiq, please see the press release here

NUBURU Establishes Advisory Board of Seasoned Technology Experts

NUBURU announced the founding members of its Advisory Board who bring global expertise across battery and e-mobility, consumer electronics, 3C and defense to guide NUBURU’s business and product development. 
 
Founding members include:
Vice Admiral (ret.) David Buss, who held numerous leadership positions throughout his 37-year career in the U.S. Navy


 
Ga-Lane Chen, Ph.D., who is currently the CTO and CIO of Foxconn
 


 
Takashi Mitachi, who is currently a Senior Advisor and was a Co-Chairman of the BCG Japan office; and 
 

 
Bob Galyen, who is recognized as one of the top executives in the battery energy storage world and science/engineering-based communities. 
  •  

To learn more about the new advisors, please see the press release here

Niron Magnetics CEO Sits Down with Adamas Intelligence for EV Motor Materials Special Feature

Adamas Intelligence recently spoke with Andy Blackburn, CEO of emerging U.S.-based permanent magnet producer, Niron Magnetics, about the company’s innovative iron nitride (“FeN”) magnet material for production of high performance, low-cost permanent magnets.
 
Blackburn explained, “Iron nitride has a very high magnetic flux density – the highest of any known compound. Flux density is proportional to torque density in motors and generators. This means with our material designers can create smaller, lighter and more cost-effective devices than with designs based on other material technologies.”

Click here to read the full Q&A. 

6K Profiled in Additive Manufacturing Magazine

6K CEO, Aaron Bent, Ph.D., spoke with Additive Manufacturing Magazine for a profile on the company’s technology and how it can help the U.S. can become self-sufficient in aerospace alloy metals powders.
 

Click here to see the full feature and learn more about the technology.

 
WELCOME TO ANZU
This past month, we were proud to welcome a new senior investment professional to the Anzu family:

Jaione Maiz, Ph.D., Principal, Life Sciences

Dr. Jaione Maiz is a Principal at Anzu Partners with a focus on investing at the intersections of life science and innovative technology. She also supports portfolio companies in business development, strategy, and product development. 
 
Prior to Anzu, Jaione was a Director of Business Development at Zymergen, supporting life science and healthcare partnerships with Fortune 500 companies. Before Zymergen, Jaione supported new drug discovery company formation, development, and partnering at Inception Sciences, an incubator within venture fund Versant Ventures.
 
Jaione has a Ph.D. in Neurobiology from UCLA, a bachelor’s from Northwestern University, and is a Kauffman Fellow.

In addition, we are excited to have the following team member join our portfolio support team:

Tawanda Mahachi

Tawanda Mahachi recently joined the team full-time after being a Summer Associate last year. He brings multi-industry experience in various roles particularly Systems Analysis and Product Management. His focus areas include process engineering as well as digital solutions design and development. 

While in the VC Bootcamp program, he supported Boston MicroFluidics (BMF) developing end to end visibility throughout the value chain from kit manufacture to patient testing as well as enabling patients digital access to their test results.

CAREER OPPORTUNITIES

Our portfolio companies are hiring! Browse the open roles here and learn more about joining our amazing teams.

We are looking for experts across Engineering, Life Sciences, Sales and Business Development, Product, Operations, and Marketing and Communications.

VIEW OPEN ROLES
FOLLOW US

To stay up to date on the latest news from both Anzu and our portfolio companies, follow us on social media.

Twitter Twitter
LinkedIn LinkedIn

Copyright © 2021 Anzu Partners, All rights reserved.

You are receiving this email because you requested to be added to Anzu Partners' monthly newsletter distribution list. 


We take the privacy of our subscribers very seriously. View our Privacy Policy.

Would you like to change how you receive these emails?
You can update your preferences or unsubscribe from this list.